

25th July, 2018

**BSE Limited** 

1<sup>st</sup> Floor, New Trading Wing, Rotunda Bldg, P.J. Towers, Dalal Street, Fort, Mumbai- 400 001

National Stock Exchange of India Ltd., Exchange Plaza, 5<sup>th</sup> Floor,

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra-Kurla Complex, Mumbai – 400 051.

Dear Sir / Madam,

BSE SCRIP CODE – 500302, 912459 NSE SYMBOL – PEL

Sub: Intimation of Conference Call with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details of the Conference Call with investors/analysts.

Kindly take the above on record.

Thanking you,

Yours truly,

For Piramal Enterprises Limited

Leonard D'Souza Company Secretary

Encl: a/a



# **Piramal Enterprises Limited**

## First Quarter ended 30 June 2018 Earnings Conference Call

Mumbai, India, July 25, 2018: Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302) will be hosting a conference call of investors / analysts with Chairman & its Management team on 30<sup>th</sup> July 2018 (Monday) at 5:30 PM (IST) to discuss Q1 FY2019 Results.

The dial-in numbers for the call are as below:

Event	Location & Time	Telephone Number
Conference call on		+91 22 6280 1264 / +91 22 7115 8165 (Primary Number)
30 July 2018	India – 5:30 PM IST	+91 70456 71221 (Local Number)
		1800 120 1221 / 1800 266 1221 (Toll free number)
	USA – 8:00 AM	Toll free number
	(Eastern Time – New York)	18667462133
	UK – 01:00 PM	Toll free number
	(London Time)	08081011573
	Singapore – 8:00 PM	Toll free number
	(Singapore Time)	8001012045
	Hong Kong – 8:00 PM	Toll free number
	(Hong Kong Time)	800964448
For online	http://services.choruscall.in/diamondpass/registration?confirmationNumber=2431417	
registration		

For further information, please contact:

### For Investors:

Hitesh Dhaddha / Devanshi Dhruva | Investor Relations Piramal Enterprises Limited

Contact: +91 22 3046 6306 / +91 22 3046 6376

investor.relations@piramal.com

#### For Media Queries:

Dimple Kapur | Corporate Communications

Contact: +91 22 3351 4269 dimple.kapur@piramal.com

#### **About Piramal Enterprises Ltd:**

Piramal Enterprises Limited (PEL) is one of India's large diversified companies, with a presence in Financial Services, Pharmaceuticals and Healthcare Insights & Analytics. PEL's consolidated revenues were over US\$1.6 billion in FY2018, with around 46% of revenues generated from outside India.

In Financial Services, Piramal Capital & Housing Finance Ltd is registered as a housing finance company with National Housing Bank (NHB) and engaged in various financial services businesses. It provides both wholesale and retail funding opportunities across sectors. In real estate, the platform provides housing finance and other financing solutions across the entire capital stack ranging from early stage private equity, structured debt, senior secured debt, construction finance, and flexi lease rental discounting. The wholesale business in non-real estate sector includes separate verticals - Corporate Finance Group (CFG) and Emerging Corporate Lending (ECL). CFG provides customized funding solutions to companies across sectors such as infrastructure, renewable energy, roads, industrials, auto components etc. while ECL focuses on lending towards Small and Medium Enterprises (SMEs). PCHFL through its group companies provides customized strategies for institutional and retail investors such as Mumbai Redevelopment Fund and Apartment Fund focused (through Piramal Fund Management) and strategic partnerships with leading global pension funds such as CPPIB, APG and Ivanhoe Cambridge. The division has also launched a Distressed Asset Investing platform with Bain Capital Credit - IndiaRF that will invest in equity and/or debt in assets across sectors (other than real estate) to drive restructuring with active participation in turnaround. PEL also has long term equity investments worth ~US\$1 billion in Shriram Group, a leading financial conglomerate in India.

In Pharma, through an end-to-end manufacturing capabilities across 13 global facilities and a large global distribution network to over 100 countries, PEL sells a portfolio of niche differentiated pharma products and provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.). The Company is also strengthening its presence in the Consumer Product segment in India.

PEL's Healthcare Insights & Analytics business is the premier provider of healthcare analytics, data & insight products and services to the world's leading pharma, biotech and medical technology companies and enables them to take informed business decisions.

PEL is listed on the BSE Limited and the National Stock Exchange of India Limited in India.